Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(3):340–343. doi: 10.1054/bjoc.2000.1613

Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?

D M Berney 1, J Shamash 2, W F Hendry 3, A Arora 1, S Jordan 1, R T Oliver 2
PMCID: PMC2363736  PMID: 11161398

Abstract

Salvage chemotherapy has been used by some oncology centres for patients with residual malignant or immature elements in retroperitoneal lymph node dissections removed for metastatic non-seminomatous germ cell tumours. However, surveillance of these patients shows that many are cured by surgery alone. 118 retroperitoneal lymph node dissections for metastatic non-seminomatous germ cell tumours were reviewed and the morphology seen within them was quantified. 28 of these had immature or malignant elements and had been treated by surveillance before administration of further chemotherapy. The proliferation rate in these cases was assessed by immunochemistry. The proliferation index and the amount of embryonal carcinoma (EC) were both predictors of recurrence and therefore the need for further chemotherapy. Patients with greater than 25% of EC had an 84% chance of relapse and those with a Ki-67 index of greater than 50% had a 71% chance of relapse. The two tests had a positive predictive value of 83% and 71%, respectively. Patients with such a high risk of recurrence could be considered for post-operative adjuvant therapy at this point whilst others would be suitable for a watchful waiting approach. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: embryonal carcinoma, Ki-67, lymph node

Full Text

The Full Text of this article is available as a PDF (52.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers P., Bierhoff E., Neu D., Fimmers R., Wernert N., Müller S. C. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer. 1997 May 1;79(9):1710–1716. [PubMed] [Google Scholar]
  2. Albers P., Ganz A., Hannig E., Miersch W. D., Müller S. C. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000 Aug;164(2):381–384. [PubMed] [Google Scholar]
  3. Albers P., Miller G. A., Orazi A., Ulbright T. M., Albers J., Donohue J. P., Foster R. S. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer. 1995 Feb 1;75(3):844–850. doi: 10.1002/1097-0142(19950201)75:3<844::aid-cncr2820750316>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  4. Aprikian A. G., Herr H. W., Bajorin D. F., Bosl G. J. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer. 1994 Aug 15;74(4):1329–1334. doi: 10.1002/1097-0142(19940815)74:4<1329::aid-cncr2820740424>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  5. Eid H., Gulyás M., Géczi L., Bodrogi I., Institoris E., Bak M. Expression of bcl-2 in testicular carcinoma: correlation with tumor progression and MDR1/Pgp. Cancer. 1998 Jul 15;83(2):331–336. doi: 10.1002/(sici)1097-0142(19980715)83:2<331::aid-cncr17>3.3.co;2-3. [DOI] [PubMed] [Google Scholar]
  6. Einhorn L. H., Williams S. D., Mandelbaum I., Donohue J. P. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer. 1981 Aug 15;48(4):904–908. doi: 10.1002/1097-0142(19810815)48:4<904::aid-cncr2820480407>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  7. Fernandez E. B., Sesterhenn I. A., McCarthy W. F., Mostofi F. K., Moul J. W. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol. 1994 Oct;152(4):1133–1138. doi: 10.1016/s0022-5347(17)32522-3. [DOI] [PubMed] [Google Scholar]
  8. Fox E. P., Weathers T. D., Williams S. D., Loehrer P. J., Ulbright T. M., Donohue J. P., Einhorn L. H. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993 Jul;11(7):1294–1299. doi: 10.1200/JCO.1993.11.7.1294. [DOI] [PubMed] [Google Scholar]
  9. Gerdes J., Li L., Schlueter C., Duchrow M., Wohlenberg C., Gerlach C., Stahmer I., Kloth S., Brandt E., Flad H. D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991 Apr;138(4):867–873. [PMC free article] [PubMed] [Google Scholar]
  10. Heidenreich A., Schenkmann N. S., Sesterhenn I. A., Mostofi F. K., McCarthy W. F., Heidenreich B., Moul J. W. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. J Urol. 1997 Aug;158(2):620–625. [PubMed] [Google Scholar]
  11. Heidenreich A., Sesterhenn I. A., Mostofi F. K., Moul J. W. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer. 1998 Sep 1;83(5):1002–1011. [PubMed] [Google Scholar]
  12. Herr H. W. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol. 1997 Oct;80(4):653–657. doi: 10.1046/j.1464-410x.1997.00427.x. [DOI] [PubMed] [Google Scholar]
  13. Javadpour N., Young J. D., Jr Prognostic factors in nonseminomatous testicular cancer. J Urol. 1986 Mar;135(3):497–499. doi: 10.1016/s0022-5347(17)45705-3. [DOI] [PubMed] [Google Scholar]
  14. Lee C. Cellular interactions in prostate cancer. Br J Urol. 1997 Mar;79 (Suppl 1):21–27. doi: 10.1111/j.1464-410x.1997.tb00797.x. [DOI] [PubMed] [Google Scholar]
  15. Leonardi E., Girlando S., Serio G., Mauri F. A., Perrone G., Scampini S., Dalla Palma P., Barbareschi M. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992 May;45(5):416–419. doi: 10.1136/jcp.45.5.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Little J. S., Jr, Foster R. S., Ulbright T. M., Donohue J. P. Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy. J Urol. 1994 Oct;152(4):1144–1149. doi: 10.1016/s0022-5347(17)32524-7. [DOI] [PubMed] [Google Scholar]
  17. Loehrer P. J., Sr, Gonin R., Nichols C. R., Weathers T., Einhorn L. H. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998 Jul;16(7):2500–2504. doi: 10.1200/JCO.1998.16.7.2500. [DOI] [PubMed] [Google Scholar]
  18. Michael H., Lucia J., Foster R. S., Ulbright T. M. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol. 2000 Feb;24(2):257–273. doi: 10.1097/00000478-200002000-00012. [DOI] [PubMed] [Google Scholar]
  19. Ravi R., Oliver R. T., Ong J., Badenoch D. F., Fowler C. G., Paris A. M., Hendry W. F. A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol. 1997 Oct;80(4):647–652. doi: 10.1046/j.1464-410x.1997.00410.x. [DOI] [PubMed] [Google Scholar]
  20. Richie J. P., Kantoff P. W. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol. 1991 Aug;9(8):1393–1396. doi: 10.1200/JCO.1991.9.8.1393. [DOI] [PubMed] [Google Scholar]
  21. Shamash J., Oliver R. T., Ong J., Raja M., Edmonds P., Gallagher C. J., Ostrowski M. J., LeVay J., Williams M. Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy. Ann Oncol. 1999 Jun;10(6):685–692. doi: 10.1023/a:1008318612005. [DOI] [PubMed] [Google Scholar]
  22. Stattin P., Damber J. E., Karlberg L., Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol. 1997 Jan;157(1):219–222. [PubMed] [Google Scholar]
  23. Stenning S. P., Parkinson M. C., Fisher C., Mead G. M., Cook P. A., Fossa S. D., Horwich A., Jones W. G., Newlands E. S., Oliver R. T. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer. 1998 Oct 1;83(7):1409–1419. [PubMed] [Google Scholar]
  24. Steyerberg E. W., Keizer H. J., Fosså S. D., Sleijfer D. T., Toner G. C., Schraffordt Koops H., Mulders P. F., Messemer J. E., Ney K., Donohue J. P. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995 May;13(5):1177–1187. doi: 10.1200/JCO.1995.13.5.1177. [DOI] [PubMed] [Google Scholar]
  25. Tait D., Peckham M. J., Hendry W. F., Goldstraw P. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer. 1984 Nov;50(5):601–609. doi: 10.1038/bjc.1984.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Toner G. C., Panicek D. M., Heelan R. T., Geller N. L., Lin S. Y., Bajorin D., Motzer R. J., Scher H. I., Herr H. W., Morse M. J. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990 Oct;8(10):1683–1694. doi: 10.1200/JCO.1990.8.10.1683. [DOI] [PubMed] [Google Scholar]
  27. Williams S. D., Stablein D. M., Einhorn L. H., Muggia F. M., Weiss R. B., Donohue J. P., Paulson D. F., Brunner K. W., Jacobs E. M., Spaulding J. T. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 1987 Dec 3;317(23):1433–1438. doi: 10.1056/NEJM198712033172303. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES